Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/jamasurg.2013.3668 | DOI Listing |
Surg Endosc
January 2025
Department of Medicine, Surgery and Healthcare Sciences, University of Trieste, Strada Di Fiume 447, 34149, Trieste, Italy.
Background: Climate change poses significant challenges to global health, exacerbated by healthcare systems' carbon footprint and waste generation. Surgical activities contribute to these impacts, necessitating sustainable practices to mitigate environmental harm. This study aims to assess the feasibility and effectiveness of a recycling program in reducing waste, carbon emissions, and disposal costs in the operating rooms (ORs).
View Article and Find Full Text PDFAm J Phys Med Rehabil
September 2024
School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.
This review systematically examined the reporting of sex and female participation in post-stroke lower extremity (LE) motor rehabilitation randomized controlled trials (RCTs) over time and identified differences in female participation across RCTs conducted in low-and-middle-income countries (LMICs), high-income-countries (HICs), and HIC-regions. Systematic searches were conducted of MEDLINE, Embase, CINAHL and PsycINFO from 1970 to May 2022. RCTs in English were included if they examined post-stroke LE motor rehabilitation interventions in adults diagnosed with stroke.
View Article and Find Full Text PDFJ Atten Disord
December 2024
Deakin University, Melbourne, VIC, Australia.
Objectives: To determine ADHD research priorities from the perspective of ADHD professionals internationally.
Method: A two-stage modified Delphi design was used. In Stage 1 (qualitative), participants listed research questions relating to ADHD that they perceived to be most important ( = 132).
BMC Glob Public Health
September 2024
Global Antibiotic Research & Development Partnership, Geneva, Switzerland.
New, first-in-class oral antibiotics like zoliflodacin, developed in a public-private partnership, require an optimal introduction strategy while ensuring antibiotic stewardship. Zoliflodacin, given as a single dose for uncomplicated urogenital gonorrhoea, recently demonstrated non-inferiority to ceftriaxone plus azithromycin and safety in a phase 3 randomised controlled trial. Following regulatory approval, zoliflodacin could improve sexually transmitted infection (STI) management and help address the threat of untreatable gonorrhoea, as levels of resistance to current first-line treatments increase.
View Article and Find Full Text PDFBMC Glob Public Health
October 2024
Department of Physiology, Faculty of Biomedical and Psychological Sciences, Monash Biomedicine Discovery Institute, Clayton, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!